Arvinas (Arvinas) FCF Margin % : -385.77% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Arvinas FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Arvinas's Free Cash Flow for the three months ended in Mar. 2024 was $-97.60 Mil. Arvinas's Revenue for the three months ended in Mar. 2024 was $25.30 Mil. Therefore, Arvinas's FCF Margin % for the quarter that ended in Mar. 2024 was -385.77%.

As of today, Arvinas's current FCF Yield % is -16.59%.

The historical rank and industry rank for Arvinas's FCF Margin % or its related term are showing as below:

ARVN' s FCF Margin % Range Over the Past 10 Years
Min: -499.3 Med: -172.81 Max: 1034.89
Current: -499.3

During the past 8 years, the highest FCF Margin % of Arvinas was 1034.89%. The lowest was -499.30%. And the median was -172.81%.

ARVN's FCF Margin % is ranked worse than
67.05% of 1044 companies
in the Biotechnology industry
Industry Median: -146.375 vs ARVN: -499.30

Arvinas FCF Margin % Historical Data

The historical data trend for Arvinas's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arvinas FCF Margin % Chart

Arvinas Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-109.07

-371.04

1,034.89

-213.32

-446.75

Arvinas Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-284.00	-163.85	-248.27	193.04	-385.77

Competitive Comparison of Arvinas's FCF Margin %

For the Biotechnology subindustry, Arvinas's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arvinas's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arvinas's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Arvinas's FCF Margin % falls into.

Arvinas FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Arvinas's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-350.7	/	78.5
	=	-446.75 %

Arvinas's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-97.6	/	25.3
	=	-385.77 %

Arvinas FCF Margin % Related Terms

Thank you for viewing the detailed overview of Arvinas's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Arvinas (Arvinas) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arvinas Inc (NAS:ARVN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Winchester Avenue, 5 Science Park, New Haven, CT, USA, 06511

Website

https://www.arvinas.com

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Executives

Ronald Peck	officer: Chief Medical Officer	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Sunil Agarwal	director	60 LEVERONI COURT, NOVATO CA 94949
Ian Taylor	officer: Senior Vice President, Biology	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 0651
John G Houston	director, officer: President and CEO	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Sean A Cassidy	officer: Chief Financial Officer	322 EAST MAIN STREET, BRANFORD CT 06405
Everett Cunningham	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
David K Loomis	officer: Chief Accounting Officer	C/O 5 SCIENCE PARK, 385 WINCHESTER AVENUE, NEW HAVEN CT 06511
John D Young	director	C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Briggs Morrison	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Liam Ratcliffe	director, 10 percent owner	C/O ACCESS INDUSTRIES, INC, 40 WEST 57TH ST, 28TH FLOOR, NEW YORK NY 10019
Timothy M Shannon	director	C/O CURAGEN CORP, 555LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Bradley Albert Margus	director	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Kennedy Edward Moore Jr.	director	C/O ARVINAS, INC. 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Wendy L Dixon	director
Linda Bain	director	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139